- Category: Experimental HIV Drugs
- Published on Monday, 04 March 2013 00:00
- Written by Gregory Fowler
Research towards a cure for HIV is a key theme of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), taking place this week in Atlanta. One of the many approaches under study is the use of small molecules to bring resting HIV out of latency, in an effort to ultimately eradicate the virus from the body.
Daria Hazuda from Merck Research Laboratories gave the annual Bernard Fields Lecture on the opening day of the conference, discussing efforts to develop the integrase inhibitor class of antiretroviral drugs. Lessons learned from integrase development are now informing efforts to develop therapies that may lead to a functional cure for HIV, enabling people to stop taking antiretroviral therapy without disease progression.
[Matt Sharp interviews Daria Hazuda for HIVandHepatitis.com at CROI 2013 in Atlanta, March 4, 2013]
D Hazuda. ARV Drug Discovery: Integrase Inhibitors and Beyond.Bernard Fields Lecture.20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, March 3-6, 2013. Abstract 14.